[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526033":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":64,"collaborators":66,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":18,"enrollmentInfo":92,"targetDuration":18,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":54,"whyStopped":18,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"University of Bern","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DROPIT Intervention","EXPERIMENTAL","The study intervention is a patient-centred PPI deprescribing intervention aiming to guide GPs and patients through the process of safely deprescribing inappropriate PPIs.",[13],"Other: Proton Pump Inhibitor deprescribing tool",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","NO_INTERVENTION","The reference or control arm will receive usual care. This means that the GPs and patients in this group will conduct their clinical practice as per usual, without receiving the intervention from the study team.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Proton Pump Inhibitor deprescribing tool","The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.",[9],[25],{"name":26,"affiliation":27,"role":28},"Sven Streit, Prof. Dr. med. Dr. phil","University of Bern, Institute of Primary Health Care (BIHAM)","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Sven Streit, Prof. Dr med. Dr. phil.","CONTACT","+41 31 684 58 75","sven.streit@unibe.ch",[36,53],{"facility":37,"status":38,"city":39,"state":18,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Prof. Dr. med. Dr. phil. Sven Streit","NOT_YET_RECRUITING","Bern","3012","Switzerland","CH",{"type":44,"coordinates":45},"Point",[46,47],7.44744,46.94809,{"lat":47,"lon":46},[50,52],{"name":51,"role":32,"phone":33,"phoneExt":18,"email":34},"Sven Streit, Prof. Dr. med. Dr. phil.",{"name":51,"role":28,"phone":18,"phoneExt":18,"email":18},{"facility":5,"status":54,"city":39,"state":18,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":55,"geoPoint":57,"contacts":58},"RECRUITING",{"type":44,"coordinates":56},[46,47],{"lat":47,"lon":46},[59,63],{"name":60,"role":32,"phone":61,"phoneExt":18,"email":62},"Sven Streit Prof. Dr. Dr. med","+41 31 631 58 70","dropit.biham@unibe.ch",{"name":60,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":65,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[67,69,71,73,75,78,80],{"name":68,"class":6},"Swiss National Science Foundation",{"name":70,"class":6},"University of Zurich",{"name":72,"class":6},"University of Basel",{"name":74,"class":6},"Insel Gruppe AG, University Hospital Bern",{"name":76,"class":77},"Patientenstelle Zürich","UNKNOWN",{"name":79,"class":77},"Patientenstelle Basel",{"name":81,"class":6},"Centre Hospitalier Universitaire Vaudois","100526033","deprescribing-inappropriate-proton-pump-inhibitors-100526033",false,"NCT06129474","Deprescribing Inappropriate Proton Pump Inhibitors","DepRescribing inapprOpriate Proton Pump InhibiTors - the DROPIT Trial: a Cluster Randomized Controlled Trial in Primary Care Setting","DROPIT","Inclusion Criteria:\n\n1. Patient of a participating GP.\n2. Age: minimum 18 years old.\n3. Daily PPI intake for minimum 8 weeks.\n4. PPI in one of the following doses:\n\n   * minimum 40mg\u002Fday pantoprazole;\n   * minimum 40mg\u002Fday omeprazole;\n   * more than 30mg\u002Fday lansoprazole;\n   * more than 30mg\u002Fday dexlansoprazole;\n   * more than 20mg\u002Fday esomeprazole;\n   * more than 20mg\u002Fday rabeprazole.\n5. Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment.\n\nExclusion Criteria:\n\n1. Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.\n2. Unable to provide informed consent.\n3. PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:\n\n   * History of bleeding ulcer.\n   * Peptic ulcer due to cause other than NSAID or H. Pylori.\n   * Barrett's oesophagus.\n   * Severe erosive reflux disease (Los Angeles grade C\u002FD).\n   * GERD with symptoms or complications (oesophageal ulcer, peptic stricture).\n   * Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea refractory to enzyme replacement therapy, idiopathic pulmonary fibrosis.)\n4. Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below.\n\nMedications (any dose):\n\n* Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days.\n* Antiplatelet therapy.\n* Additional antiplatelet therapy (e.g., ticagrelor or similar).\n* Anticoagulant(s).\n* Systemic steroid(s) for more than 1 month.\n\nRisk factors:\n\n* History of gastrointestinal ulcer.\n* Age of 75 years and older.\n* Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use.\n* Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).","ALL","18 Years",{"count":93,"type":94},400,"ESTIMATED","INTERVENTIONAL",[97],"NA","The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.",[100,101,102],"Inappropriate Prescribing","Reflux Disease","Proton Pump Inhibitors",[104,105],"Deprescribing","Proton pump inhibitors","2026-05-11",{"date":108,"type":109},"2026-05-14","ACTUAL",{"date":111,"type":109},"2024-10-01",{"date":113,"type":94},"2027-12-31",{"name":5,"class":6},2]